Introduction
Triggering and the pathophysiology of acute coronary syndromes
Antiplatelet therapy: Do the new platelet inhibitors add significantly to the clinical benefits of aspirin?
Sucessors to heparin: New antithrombotic agents
The evolution of antithrombotic therapy in coronary stenting
Rationale for low-molecular weight heparin in coronary stenting
Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease